{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:40:37Z","timestamp":1793054437923,"version":"4.5.0"},"reference-count":70,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Soc Stud Sci"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>How does a compound become a drug, and how do we decide for whom the drug is intended? Building a history of modafinil, this article examines how classification and serendipity affect drug development. We explore how mental health categories interact with drug development by tracing: how compound CRL40,476 was inadvertently created while exploring other compounds, and then became a focal point for development efforts; and how it secured Schedule IV status (low potential for abuse), orphan drug status (for niche markets), and then blockbuster drug status (&gt;$1bn in annual sales). Classification of modafinil and its uses were negotiated under conditions of uncertainty, requiring substantial efforts to align interests across a wide array of institutions. We highlight these contingencies to show the considerable efforts that go into finding, and creating, markets for drug development. Taking these efforts for granted may confuse invention with innovation and is likely to lead to understatement of the costs and choices involved in drug development, particularly where mental health categories are concerned.<\/jats:p>","DOI":"10.1177\/03063127251322113","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T09:20:32Z","timestamp":1742289632000},"page":"842-861","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Making modafinil: Classification and serendipity in drug development"],"prefix":"10.1177","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4976-4215","authenticated-orcid":false,"given":"Stephen J","family":"Scholte","sequence":"first","affiliation":[{"name":"Science Policy Research Unit (SPRU), University of Sussex, Brighton, East Sussex, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9913-417X","authenticated-orcid":false,"given":"Ohid","family":"Yaqub","sequence":"additional","affiliation":[{"name":"Science Policy Research Unit (SPRU), University of Sussex, Brighton, East Sussex, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"e_1_3_5_2_1","author":"AFSSAPS","year":"2011","unstructured":"AFSSAPS. (2011). Communiqu\u00e9 de presse Point d\u2019information sur les dossiers discut\u00e9s en commission d\u2019AMM S\u00e9ance du jeudi 1er d\u00e9cembre 2011. https:\/\/documents.resip.fr\/003026.pdf","journal-title":"Communiqu\u00e9 de presse Point d\u2019information sur les dossiers discut\u00e9s en commission d\u2019AMM S\u00e9ance du jeudi 1er d\u00e9cembre 2011"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S23624"},{"key":"e_1_3_5_4_1","volume-title":"Audition du Docteur Yves COQUIN, Sous-directeur \u00e0 la direction g\u00e9n\u00e9rale de la Sant\u00e9","author":"Assembl\u00e9e nationale","year":"2000","unstructured":"Assembl\u00e9e nationale. (2000). Audition du Docteur Yves COQUIN, Sous-directeur \u00e0 la direction g\u00e9n\u00e9rale de la Sant\u00e9. R\u00e9seau Voltaire. https:\/\/www.voltairenet.org\/article9960.html"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2018.07.010"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0278-5846(88)90014-0"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2018.05.027"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/2398212818816018"},{"key":"e_1_3_5_9_1","author":"Carlat","year":"2013","unstructured":"Carlat. (2013). Provigil: Does it have the Midas touch? The Carlat Psychiatry Report, May 18.","journal-title":"Provigil: Does it have the Midas touch?"},{"key":"e_1_3_5_10_1","volume-title":"National Health Interview Survey - 1997-2018","author":"CDC","year":"2021","unstructured":"CDC. (2021). National Health Interview Survey - 1997-2018. Center for Disease Control."},{"key":"#cr-split#-e_1_3_5_11_1.1","unstructured":"Cephalon Inc. (2004). Form 10-K: Annual report pursuant to section 13 or 15"},{"key":"#cr-split#-e_1_3_5_11_1.2","unstructured":"(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31 2003. United States Securities and Exchange Commission. Retrieved September 18 2024 from https:\/\/www.sec.gov\/Archives\/edgar\/data\/873364\/000104746904007646\/a2129657z10-k.htm"},{"key":"#cr-split#-e_1_3_5_12_1.1","unstructured":"Cephalon Inc. (2011). Form 10-K: Annual report pursuant to section 13 or 15"},{"key":"#cr-split#-e_1_3_5_12_1.2","unstructured":"(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31 2010. United States Securities and Exchange Commission. Retrieved September 18 2024 from https:\/\/www.sec.gov\/Archives\/edgar\/data\/873364\/000104746911000780\/a2201824z10-k.htm"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.1987.tb00563.x"},{"key":"e_1_3_5_14_1","volume-title":"N\u00b03055\u2014RAPPORT D\u2019INFORMATION -Engagement des militaires fran\u00e7ais\u2014Guerre du Golfe\u2014Balkans: Risques sanitaires sp\u00e9cifiques","author":"Commission De La D\u00e9fense","year":"2001","unstructured":"Commission De La D\u00e9fense. (2001). N\u00b03055\u2014RAPPORT D\u2019INFORMATION -Engagement des militaires fran\u00e7ais\u2014Guerre du Golfe\u2014Balkans: Risques sanitaires sp\u00e9cifiques. http:\/\/www.assemblee-nationale.fr\/rap-info\/i3055-02.asp"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.56021\/9780801885846"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/21677026211017834"},{"key":"e_1_3_5_17_1","first-page":"203","volume-title":"Advances in medical sociology","author":"Coveney C. M.","year":"2011","unstructured":"Coveney C. M. (2011). Cognitive enhancement? Exploring modafinil use in social context. In Pickersgill M., Van Keulen I. (Eds.), Advances in medical sociology (pp. 203\u2013228). Emerald Group Publishing Limited."},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/1467-9566.12046"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2008.11.016"},{"key":"e_1_3_5_20_1","volume-title":"Sedated: How modern capitalism created our mental health crisis","author":"Davies J.","year":"2021","unstructured":"Davies J. (2021). Sedated: How modern capitalism created our mental health crisis. Atlantic Books."},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0025-y"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/27.8.1453"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(79)90033-5"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41606-018-0027-x"},{"key":"e_1_3_5_25_1","author":"FDA","year":"1998","unstructured":"FDA. (1998). Drug approval package: Provigil (Modafinil) NDA# 20717. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/020717A_Provigil.cfm","journal-title":"Drug approval package: Provigil (Modafinil) NDA# 20717"},{"key":"e_1_3_5_26_1","author":"FDA","year":"2002","unstructured":"FDA. (2002). Warning letter, Cephalon Inc. (Provigil (modafinil) Tablets). https:\/\/web.archive.org\/web\/20020614102450\/http:\/\/www.pharmcast.com\/WarningLetters\/Yr2002\/Jan2002\/Cephalon0102.htm","journal-title":"Warning letter, Cephalon Inc. (Provigil (modafinil) Tablets)"},{"key":"e_1_3_5_27_1","author":"FDA","year":"2017","unstructured":"FDA. (2017). New dietary ingredient application letter, Adrafinil. https:\/\/www.regulations.gov\/document\/FDA-2017-S-0023-0036","journal-title":"New dietary ingredient application letter, Adrafinil"},{"key":"e_1_3_5_28_1","volume-title":"Saving normal: An insider\u2019s revolt against out-of-control psychiatric diagnosis, DSM-5, big pharma, and the medicalization of ordinary life","author":"Frances A.","year":"2014","unstructured":"Frances A. (2014). Saving normal: An insider\u2019s revolt against out-of-control psychiatric diagnosis, DSM-5, big pharma, and the medicalization of ordinary life. William Morrow, an imprint of HarperCollins Publishers."},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4808-644"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/0162243908329567"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respol.2016.01.007"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2022.01083"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1515\/9781400821686"},{"key":"e_1_3_5_34_1","author":"Hansard","year":"2004","unstructured":"Hansard. (2004). House of Commons written answers for 11 Oct (pt 18) and 28 Oct (pt 19). https:\/\/publications.parliament.uk\/pa\/cm200304\/cmhansrd\/vo041028\/text\/41028w19.htm","journal-title":"House of Commons written answers for 11 Oct (pt 18) and 28 Oct (pt 19)"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291710001844"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031894"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.9.1063"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868130-00003"},{"key":"e_1_3_5_39_1","unstructured":"Lafon L. (1978). United States Patent: 4066686 - New benzhydrysulphinyl derivatives."},{"key":"e_1_3_5_40_1","unstructured":"Lafon L. (1979). United States Patent: 4177290 - Acetamide derivatives."},{"key":"e_1_3_5_41_1","volume-title":"Sustained\/continuous operations subgroup of the department of defense human factors engineering technical group","author":"LaGarde D.","year":"1990","unstructured":"LaGarde D. (1990). Sustained\/continuous operations subgroup of the department of defense human factors engineering technical group. Naval Aerospace Medical Research Laboratory."},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.314"},{"key":"e_1_3_5_43_1","volume-title":"Science in action: How to follow scientists and engineers through society","author":"Latour B.","year":"1986","unstructured":"Latour B. (1986). Science in action: How to follow scientists and engineers through society. Open University Press."},{"key":"e_1_3_5_44_1","volume-title":"The pasteurization of France","author":"Latour B.","year":"1988","unstructured":"Latour B. (1988). The pasteurization of France. Harvard University Press."},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2018.06.008"},{"key":"e_1_3_5_46_1","volume-title":"The social shaping of technology","author":"MacKenzie D.","year":"1999","unstructured":"MacKenzie D., Wajcman J. (1999). The social shaping of technology. Open University Press."},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.3892\/br.2017.909"},{"key":"e_1_3_5_48_1","unstructured":"Medicines and Healthcare products Regulatory Agency. (2010). Modafinil: Restricted use recommended. Retrieved March 7 2024 from https:\/\/www.gov.uk\/drug-safety-update\/modafinil-restricted-use-recommended"},{"issue":"4","key":"e_1_3_5_49_1","first-page":"372","article-title":"Effects of adrafinil (CRL 40028) on the nocturnal activity of rhesus monkeys","volume":"16","author":"Milhaud C. L.","year":"1985","unstructured":"Milhaud C. L., Klein M. J. (1985). Effects of adrafinil (CRL 40028) on the nocturnal activity of rhesus monkeys. Journal de Pharmacologie, 16(4), 372\u2013380.","journal-title":"Journal de Pharmacologie"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/icc\/9.2.315"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respol.2004.08.008"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/09505431.2010.508086"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-9566.2011.01404.x"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/1467-9566.13029"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1080\/17449642.2018.1443050"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/B0-08-045044-X\/00300-X"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1745855206004078"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/1468-0009.t01-1-00003"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1353\/pbm.2015.0008"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2016.07.002"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11030355"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.28938\/9780995527775"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103648"},{"key":"e_1_3_5_64_1","unstructured":"US Department of Justice. (2008 September 29). Pharmaceutical company Cephalon to pay $425 million for off-label drug marketing. Retrieved September 18 2024 from https:\/\/www.usdoj.gov\/usao\/pae"},{"key":"e_1_3_5_65_1","unstructured":"US Drug Enforcement Administration. (2025). Drug scheduling. Retrieved January 17 2025 from https:\/\/www.dea.gov\/drug-information\/drug-scheduling"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4609"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respol.2016.12.001"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respol.2017.10.007"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2012.07.023"}],"container-title":["Social Studies of Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03063127251322113","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03063127251322113","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03063127251322113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T19:35:35Z","timestamp":1777664135000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03063127251322113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1177\/03063127251322113"],"URL":"https:\/\/doi.org\/10.1177\/03063127251322113","relation":{},"ISSN":["0306-3127","1460-3659"],"issn-type":[{"value":"0306-3127","type":"print"},{"value":"1460-3659","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]}}}